Online inquiry

IVTScrip™ mRNA-Anti-CD70, SGN-75(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14824MR)

This product GTTS-WQ14824MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD70 gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001252.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 970
UniProt ID P32970
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD70, SGN-75(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ14824MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8542MR IVTScrip™ mRNA-Anti-CD4, Hu5A8(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA Hu5A8
GTTS-WQ11767MR IVTScrip™ mRNA-Anti-CTLA4, MK-1308(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MK-1308
GTTS-WQ5473MR IVTScrip™ mRNA-Anti-tcdB, CDB-1(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CDB-1
GTTS-WQ273MR IVTScrip™ mRNA-Anti-EPCAM, 17-1A(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA 17-1A
GTTS-WQ11402MR IVTScrip™ mRNA-Anti-PDGFRA, MEDI-575(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MEDI-575
GTTS-WQ2812MR IVTScrip™ mRNA-Anti-ADCYAP1R1, AMG-301(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AMG-301
GTTS-WQ9365MR IVTScrip™ mRNA-Anti-PDCD1, INCMGA-00012(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA INCMGA-00012
GTTS-WQ6923MR IVTScrip™ mRNA-Anti-TNF, ENIA11(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ENIA11
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW